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Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. It is 
characterized by a variable clinical course ranging from mild to fatal disease. It 
can affect the kidneys. The aim of treatment in SLE is the prevention of flares and 
the prevention of accumulation of damage to the main organs affected as well as 
the prevention of drug side effects. The cornerstone of SLE treatment is hydroxy-
chloroquine. Corticosteroids are used both as induction treatment in disease flares 
as well as in small doses as maintenance treatment. Immunosuppressants, such as 
azathioprine, methotrexate and mycophenolate mofetil are used as steroid sparing 
agents. Calcineurin inhibitors, namely tacrolimus and cyclosporin A may also be 
used as immunosuppressants and steroid sparing agents. Pulse methylprednisolone, 
along with mycophenolate mofetil and cyclophosphamide are used as induction 
treatment in lupus nephritis. Rituximab, an anti-CD20 biologic agent may be used 
in non-renal SLE. In patients insufficiently controlled with hydroxychloroquine, 
low dose prednisone and/or immunosuppressive agents, belimumab may be used 
with beneficial effects in non-renal disease and lupus nephritis.
Keywords: systemic lupus erythematosus, treatment, hydroxychloroquine, 
corticosteroids, mycophenolate mofetil, rituximab, belimumab
1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease affecting 
many organ systems. It has a variable course, ranging from a mild course to severe 
fatal disease. It affects mainly women in the reproductive age. Women of African or 
Asian origin suffer frequently and present with more severe disease. The treatment 
of SLE is in the focus of scientific interest as new immune modulating agents have 
entered the management of the disease.
The therapeutic management of the disease depends mainly on antimalarial 
agents, namely hydroxychloroquine, corticosteroids, immunosuppressive agents 
and biologic drugs (Figures 1 and 2). The use of hydroxychloroquine is established 
in SLE. Similarly, the use of corticosteroids has been in the mainstream of lupus 
treatment for many years. Their use is hindered by their adverse effects, which may 
occur even with small doses. Immunosuppressive agents such as azathioprine and 
methotrexate have been used as steroid sparing agents. The use of mycophenolate 
mofetil (MMF) is also in the mainstream treatment of severe SLE cases or lupus 
nephritis. Rituximab, an antiCD20 antibody targeting B lymphocytes has also been 
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applied in the treatment of severe SLE cases. Recently, the use of belimumab has 
been introduced in the treatment of SLE and is indicated in patients with non-
renal disease and renal disease not responsive to standard treatment. Although, 
recent advances in treatment have improved prognosis and life expectancy in lupus 
patients, much progress remains to be achieved. In the present chapter, the use of 
various treatment modalities for SLE will be discussed. Additionally, the use of 
supplementary drugs will be reviewed.
2. Systemic lupus erythematosus treatment
2.1 Antimalarials
Antimalarials have been used for many years in the treatment of rheumatic dis-
eases [1, 2]. Historically, antimalarials had been observed to ameliorate rheumatic 
symptoms in soldiers taking these drugs during World War II for the prevention 
of malaria [3]. Clinical application of hydroxychloroquine and chloroquine in the 
treatment of rheumatic diseases has been widely reported. The use of hydroxychlo-
roquine in the treatment of SLE has been well established [4, 5]. It has been used 
in both discoid lupus and SLE [6]. Chloroquine and hydroxychloroquine increase 
pH within intracellular vacuoles and modify processes such as protein degrada-
tion by acidic hydrolases in the lysosome, organization of macromolecules in the 
Figure 1. 
Agents involved in systemic lupus erythematosus treatment.
Figure 2. 
Agents contributing to the treatment of lupus nephritis.
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endosomes, and post-translation modification of proteins in the Golgi apparatus. 
The antirheumatic properties of antimalarials is a consequence of their interference 
with antigen processing in antigen-presenting cells. For the digestion of antigenic 
proteins and for the peptides to assemble with the chains of the MHC class II 
proteins it is necessary to have acidic cytoplasmic compartments. Antimalarials 
increase the pH thereby diminishing the formation of peptide-MHC protein 
complexes which are required to stimulate CD4+ T cells and down-regulating the 
immune response against autoantigenic peptides [7, 8]. It also blocks Toll-like recep-
tors on dendritic cells [9]. A review of controlled trials on the clinical efficacy and 
safety of antimalarials showed that adequate evidence exist for these drugs, in par-
ticular hydroxychloroquine in preventing lupus flares, increasing long term survival 
of patients and lupus activity in pregnant women without proven teratogenicity 
[10]. Moderate evidence exists for the prevention of irreversible organ damage, pre-
vention of bone destruction and prevention of thrombosis. Weaker evidence exists 
for the reduction in severe lupus activity, lipid levels and subclinical atherosclerosis 
[11]. Hydroxychloroquine has been shown to improve glucose metabolism [12]. 
The toxicity of antimalarials is mild, infrequent and it is usually reversible. When 
given attention to dosage hydroxychloroquine has a safer profile. Ruiz-Irastorza et 
al recommended that hydroxychloroquine should be given to all patients with lupus 
during the full course of the disease [13]. They have described hydroxychloroquine 
as being the cornerstone of lupus treatment [13]. There have been very few efforts 
on discontinuation of the drug due to its proven efficacy and the few and mild side 
effects. Hydroxychloroquine has multiple beneficial effects in SLE. It reduces lipid 
levels, thereby inhibiting atherosclerosis [14, 15]. Hydroxychloroquine has multiple 
effects on cholesterol metabolism, as it inhibits cholesterol biosynthesis, inihibits 
lysosomal hydrolysis of cholesteryl ester and stimulates the capacity of LDL recep-
tor and the activity of HMG-CoA reductase [16]. Hydroxychloroquine protects 
lupus patients from thrombosis, as it has known antithrombotic action. It reduces 
red blood sludging, blood viscosity, platelet aggregation and protects the annexin 
V “shield” from disruption by antiphospholipid antibodies [17]. Additionally, it 
reduces glucose levels via multiple mechanisms [18].
2.2 Corticosteroids
Corticosteroids have been used at large bolus doses as induction treatment as well 
as at small doses as maintenance treatment in patients with SLE [19] (Figure 1). They 
reduce disease activity as well as disease burden accrual on different organ systems 
[20]. Corticosteroids have potent immunomodulatory properties [21]. They are 
known to modulate all aspects of immune response and have strong immunosuppres-
sive and anti-inflammatory properties [22, 23]. Their effects on the immune system 
are known to be mediated mainly by their trans repression mode of action, namely 
by their ability to reduce the expression of inflammatory transcription factors [24]. 
As corticosteroids are characterized by many severe and less severe side effects such 
as propensity to infections [25, 26], blood glucose elevation [27] and osteoporosis 
[28], different immunomodulating agents have been applied in patients with SLE as 
corticosteroid sparing agents.
Methylprednisolone pulse therapy is used for the treatment of severe mani-
festations of SLE. Intravenous pulses of prednisolone rapidly immunosuppress 
patients with organ and/or life-threatening manifestations of SLE [29, 30]. The 
gold standard is 1 g/day for 3-5 days [31]. However, this treatment schedule may be 
associated with significant infectious complications and lower doses may be useful 
as well. In particular, it has been shown that a lower dose pulse methylprednisolone 
treatment schedule involving <1500 mg/3 days may have the same beneficial effects 
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and fewer adverse effects, in particular severe infections [32]. An intensive treat-
ment schedule of rituximab, cyclophosphamide and intravenous pulses of methyl-
prednisolone has been applied with excellent results in patients with SLE and severe 
organ manifestations including nephritis [33]. Patients improved significantly and 
long-term immunosuppression other than prednisone 5 mg/day was avoided.
Corticosteroids in the form of prednisone daily as maintenance treatment for 
SLE patients has been applied for years. New data show that introducing lower 
initial doses of prednisone (<15 mg/day) and thereafter tapering to low doses of 
prednisone (5 mg/day or even lower) has been shown to be effective in SLE [34–36]. 
Mild flares can be managed with transient increases of prednisone up to 15 mg/day 
with rapid reduction. In moderate severe flares the use of pulse methylprednisolone 
125 mg, 250 mg or 500 mg/day for three consecutive days is much more effective 
and less toxic than increasing oral prednisone to 0.5-1 mg/kg/day [32]. Rapid 
reduction from doses up to 30 mg/day prednisone should be performed to 5-2.5 mg/
day within few weeks. Immunosuppressive therapy should be started early in severe 
forms of the disease and when prednisone cannot be reduced to 5 mg/day or less.
2.3 Immunosuppressants
2.3.1 Azathioprine
Azathioprine is a purine analogue. It inhibits DNA synthesis by acting on pro-
liferating cells [37]. It acts on the DNA [38]. Azathioprine is metabolized to 6-mer-
captopurine through reduction by glutathione and other sulfhydryl-containing 
compounds and then enzymatically converted into 6-thiouric acid, 6-methyl-mer-
captopurine, and 6-thioguanine [38]. Ultimately, azathioprine is incorporated into 
replicating DNA and can block the de novo pathway of purine synthesis. It is this 
action that is thought to contribute to its relative specificity to lymphocytes due to 
lack of a salvage pathway. The inhibition of purine synthesis, leads to less DNA and 
RNA available for the synthesis of white blood cells, including cells of the immune 
system. Actively replicating cells, such as T cells and B cells of the immune system, 
which actively synthesize purine to make new DNA are strongly affected [39, 40]. 
Thus, immunosuppression ensues. It has been used successfully in SLE as steroid 
sparing agent and in cases of lupus flares. It can be used safely during pregnancy 
[41]. It can be used as maintenance treatment in lupus nephritis [42].
2.3.2 Methotrexate
If the disease is not controlled with up to 5 mg prednisone methotrexate can be 
used as an immunosuppressant and steroid sparing agent [43, 44]. Methotrexate 
exerts anti-inflammatory actions through some well-known and other less well-
known mechanisms [45, 46]. It inhibits dihydrofolate reductase thus diminishing 
the de novo synthesis of purines and pyrimidines by preventing the regenera-
tion from dihydrofolate of tetrahydrofolate. Tetrahydrofolate is essential for 
the generation of folate cofactors required for purine and pyrimidine synthesis 
[47]. The reduction in the levels of methyl donors, such as tetrahydrofolate and 
methyl tetrahydrofolate, by the inhibition of dihydrofolate reductase results in the 
inhibition of the generation of lymphotoxin polyamines through methionine and 
S-adenosylmethionine. The inhibition of amino-imidazole-carboxamido-ribonu-
cleotide transformylase results in an increase in intracellular amino-imidazole-car-
boxamido-ribonucleotide levels. This increase has potent inhibitory effects on AMP 
deaminase and adenosine deaminase. Thus, adenosine is accumulated. Adenosine 
confers anti-inflammatory effects [48, 49]. Methotrexate has favorable effects on 
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the joints and the skin [50]. It is teratogenic, therefore if pregnancy is contemplated 
it should be withdrawn before conception [51].
2.3.3 Mycophenolate mofetil
Mycophenolate mofetil (MMF) has been used for many years in the treatment 
of SLE. It is a potent immunosuppressing agent with efficacy in lupus nephritis [52] 
(Figure 2) and non-renal lupus [53]. It is particularly indicated in patients with lupus 
nephritis [54]. MMF is an inhibitor of purine synthesis and it acts to inhibit lympho-
cyte proliferation and nitric oxide production by activated macrophages [55]. MMF is 
a prodrug of mycophenolic acid. Mycophenolic acid is an inhibitor of inosine-5'-mo-
nophosphate dehydrogenase [55], it depletes guanosine nucleotides preferentially in 
T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-medi-
ated immune responses and antibody formation, it inhibits the glycosylation and 
expression of adhesion molecules, and the recruitment of lymphocytes and mono-
cytes into sites of inflammation, it depletes tetrahydrobiopterin and decreases the 
production of nitric oxide by inducible NO synthase without affecting the activity 
of constitutive NO synthases. By these mechanisms MMF exerts anti-inflammatory 
activity [55]. MMF quickly and persistently reduces numbers of activated B cells and 
levels of free immunoglobulin light chains [56]. Careful studies in lupus nephritis 
have established the equivalence of MMF to intravenous (I.V.) cyclophosphamide and 
its equivalence or superiority to azathioprine in the maintenance phase of treatment 
[Aspreva Lupus Management Study (ALMS), (MAINTAIN) trial] [57–61]. MMF is 
effective in non-renal lupus as well. In a systematic review of 20 case series and open-
label trials MMF was shown to benefit patients with hematological manifestations 
and refractory dermatological involvement [62]. It has also been shown to improve 
lupus arthritis. MMF has side effects including gastrointestinal symptoms, bone mar-
row suppression, infection risk and long-term risk of cancer from immunosuppres-
sion. It appears to be less toxic than cyclophosphamide. Cases of drug sensitivity to 
MMF have been reported among an Asian subgroup of patients when combined with 
high-dose corticosteroids [62–64]. By contrast, MMF appears to be more effective in 
preventing renal flares in high-risk populations such as African Americans [65].
2.3.4 Cyclophosphamide
Cyclophosphamide is an alkylating agent. It crosslinks DNA and results in 
the death of activated lymphocytes and protects glomeruli [56, 66]. It modulates 
the expression of T and B cell activation markers [67]. It has been demonstrated 
in a meta-analysis that there is a decreased risk of end-stage renal disease when 
cyclophosphamide is applied as standard of care therapy for lupus nephritis [68]. 
Cyclophosphamide has potential side effects, which include leukopenia, infection 
risk, bladder toxicity and increased risk of malignancy [69]. Consequently, cyclophos-
phamide is used as an induction treatment for severe lupus [64, 70] and is replaced by 
other agents, such as MMF and azathioprine for long-term maintenance treatment.
2.3.5 Calcineurin inhibitors
The use of calcineurin inhibitors tacrolimus and cyclosporin A in SLE is derived 
from the experience of these drugs gained in organ transplantation. These drugs 
suppress the production of cytokines, inhibit T- and B cell activation and preserve 
the renal podocyte actin cytoskeleton, thus reducing proteinuria [71]. In non-renal 
SLE cyclosporin A exhibits steroid-sparing effects, reduces disease activity and 
flares [72]. Cyclosporin A acts by modulating lymphocyte function [73, 74]. It forms 
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a complex with cyclophilin to block the phosphatase activity of calcineurin. Thus, 
it decreases the production of inflammatory cytokines by T lymphocytes [75]. 
Tacrolimus is preferentially used for lupus nephritis as it exhibits fewer side effects 
and is characterized by better long-term outcome [76]. Tacrolimus is a macrolide 
antibiotic with immunosuppressive properties. It has a mode of action similar to 
that of cyclosporin A, although the two drugs are structurally unrelated. It exerts 
its effects principally through impairment of gene expression in target cells [77]. 
Tacrolimus bonds to an immunophilin and this complex inhibits calcineurin phos-
phatase. Tacrolimus inhibits calcium-dependent events, such as interleukin-2 gene 
transcription, nitric oxide synthase activation, cell degranulation, and apoptosis. 
It also potentiates the actions of glucocorticoids. It may enhance expression of the 
transforming growth factor beta-1 gene [78]. T cell proliferation, especially type 1 
T helper cell, in response to ligation of the T cell receptor is inhibited by tacrolimus. 
Tacrolimus has been successfully applied in combination with low-dose MMF and 
corticosteroids as induction therapy in lupus nephritis [76, 79, 80]. Tacrolimus (0.075 
mg/kg/day) has been used in refractory lupus nephritis with good results [81], 
however severe drug adverse events were observed, such as a high rate of infections 
and diabetic ketoacidosis. Cyclosporin A (2.6-3.7 mg/kg/day) has also been used 
in refractory lupus nephritis with good results, however drug adverse events such 
as tremor and hypertension have been noted [81]. Voclosporin, a novel calcineurin 
inhibitor is now used in lupus nephritis and is showing promising results [82].
2.3.6 Plasmapheresis
Plasmapheresis has been used successfully in refractory cases of neuropsychiatric 
lupus [83]. Plasmapheresis has also been applied in pregnant women with active lupus 
or antiphospholipid syndrome or in cases of lupus nephritis [84]. Immunoadsorption, 
is replacing plasmapheresis and appears to have good results [84].
2.3.7 Intravenous immunoglobulin
Therapeutic intravenous immunoglobulin (IV IG) mostly consists of human 
polyspecific immunoglobulin G. IV IG has been used in patients with systemic lupus 
erythematosus and was shown to reduce the activity of the disease [85]. IV IG may be 
used in cases of refractory neuropsychiatric lupus [83] and in lupus myocarditis [86].
2.4 Biologics
Biologic drugs currently incorporated in SLE treatment are rituximab [87–89] 
and belimumab [90–93] (Figure 1). The sequential use of rituximab and belim-
umab is also under investigation [94, 95]. Other biologic agents targeting the B 
lymphocyte have also been applied [96]. Various biologic drugs have been used in 
treatment regimens for SLE patients with poor response or side effects to standard 
treatment [97]. The original goal of biologics was to induce disease remission and 
establish self-tolerance [98, 99]. This goal has not been achieved. It may be that the 
heterogeneity of disease mechanisms inherent in SLE may guide the introduction of 
cell- and cytokine- or pathway specific therapies which will be effective in various 
subgroups of SLE patients [97].
2.4.1 Rituximab
Rituximab is a humanized anti-CD20 monoclonal antibody used for B cell deple-
tion therapy. Rituximab can induce killing of CD20+ cells via various mechanisms. 
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The effects of rituximab include complement-mediated cytotoxicity and antibody-
dependent cell-mediated cytotoxicity [100]. Targeting the B cell has been proposed 
by many research studies in SLE [101]. Results from various registries have shown 
a favorable benefit-risk ratio in treatment refractory SLE [102, 103]. Rituximab has 
been shown to be safe and effective in the treatment of non-renal SLE [103]. Namely, 
it decreases disease activity, immunologic parameters and has a steroid-sparing 
effect. It can be recommended for organ-specific manifestations, such as arthritis 
and thrombocytopenia. Rituximab has been shown to be effective for certain refrac-
tory SLE patients, in particular refractory neuropsychiatric SLE [104]. Thus, it can 
be administered in this patient group. The therapeutic effect of rituximab has been 
compared with that of MMF and with that of cyclophosphamide in a trial of 54 lupus 
nephritis patients and was shown to be equally effective [105]. B cell depletion is 
observed but it is not complete, because early B cells and plasma cells do not express 
CD20 [106]. Normalization of B cell subsets has been observed in rituximab-treated 
SLE patients [101]. In the initial introduction of rituximab, it was suggested that 
complete B cell depletion might confer a better outcome for SLE [101]. However, SLE 
flares were observed after repeated rituximab infusions. These flares were thought 
to be a result of elevated circulating CD257 (BLyS) levels and high anti-dsDNA levels 
[107, 108]. Thus, it was proposed that B cell depletion with rituximab induced a surge 
in CD257 levels that may have exacerbated disease in some SLE patients [106]. In 
these individuals, rituximab depletion was followed by rapid peripheral B cell recon-
stitution, with increased circulating plasmablasts. It has been suggested that these 
plasmablasts might stimulate autoreactive T helper cells, which promote autoantibody 
production and may drive a positive feedback loop promoting disease activity [106]. 
Consequently, rituximab is considered in lupus nephritis only after cyclophosphamide 
and MMF have failed or in relapses [109]. Despite that, an analysis of the LUNAR 
study showed complete response with rituximab in cases of lupus nephritis [110].
2.4.2 Belimumab
Belimumab, the anti-CD257 monoclonal antibody, acts as a soluble CD257 
antagonist and was the first drug approved in more than 50 years by the FDA for 
SLE [111–118]. The recognition of B cells as central in the pathogenesis of SLE led to 
the development of drugs that block B cells, including antibodies to B-cell surface 
antigens, B-cell tolerogens, blockers of co-stimulatory molecules and inhibitors of 
cytokines with direct effect on B cells [119]. The BAFF/APRIL axis has been thor-
oughly investigated as these cytokines are vital to B-cell maturation and survival 
[115, 120, 121]. Belimumab is an anti-BAFF antibody. Belimumab should be consid-
ered in extrarenal lupus in patients with inadequate response to hydrochloroquine 
and corticosteroids and immunosuppressive drugs [122]. Patients with cutaneous 
and musculoskeletal manifestations are expected to respond better. Belimumab 
was tested in a study in which it was administered in lupus patients after rituximab 
[123]. The effects of belimumab on proteinuria and neuropsychiatric SLE were 
examined in a recent study. It was found that belimumab decreased proteinuria 
and improved neuropsychiatric symptoms in neuropsychiatric SLE [124]. The US 
Food and Drug Administration (FDA) has expanded the indication for belimumab 
to adults with active lupus nephritis who are receiving standard therapy. The 
expanded indication for belimumab for patients with LN is based on findings from 
the BLISS-LN phase 3 trial. In this randomized placebo controlled clinical trial on 
the effect of belimumab on lupus nephritis it was shown that belimumab led more 
patients to a primary efficacy renal response than placebo and also led to a complete 
renal response more patients than the placebo [125]. The risk of a renal related 




Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody 
[126]. In vitro studies have shown that obinutuzumab may induce superior B cell 
cytotoxicity as compared to rituximab in patients with SLE [126]. Obinutuzumab is 
considered an alternative B-cell depleting agent for the treatment of SLE [127]. It has 
been suggested that SLE patients with secondary non-response to rituximab should be 
preferentially switched to another B-cell depleting agent instead of belimumab [128].
2.4.4 Ofatumumab
Ofatumumab is a fully human anti-CD20 monoclonal antibody [129]. It induces 
antibody-dependent cell-mediated cytotoxicity and complement-dependent cyto-
toxicity in CD20-expressing B lymphocytes. Ofatumumab is highly potent in lysing 
B cells, as this appears to stem from its binding site on the short extracellular loop of 
the target CD20 protein and its slow release from the target molecule. Ofatumumab 
has been successfully applied in a patient with SLE and hypocomplementemia in 
combination with fresh frozen plasma [130]. Ofatumumab, has been used as B cell 
depleting therapy in SLE patients who developed severe infusion reactions to ritux-
imab [131]. The agent was well tolerated and may be a safe and effective alternative 
to rituximab for B cell depletion treatment in SLE.
2.4.5 Epratuzumab
Epratuzumab is a humanized monoclonal antibody [132]. It targets CD22 on B 
cells and acts as B-cell modulating treatment through inhibition of B-cell receptor 
signaling. It has been applied in SLE [133] and found to be effective in SLE patients 
with Sjogren’s syndrome [134].
2.4.6 Sifalimumab
Interferons (IFNs) are a family of potent immunostimulatory cytokines that are 
broadly divided into three subtypes, type I, type II and type III [135]. Of all the type 
I IFNs, IFNα is the most abundant and is well characterized. The role of interferons 
in autoimmunity, especially SLE is discussed [136]. Sifalimumab is a fully human 
monoclonal antibody against multiple IFN-α subtypes and has shown promise in a 
phase IIb clinical trial in SLE [137].
2.4.7 Rigerimod
Rigerimod is a peptide which reduces the stability of MHC molecules that present 
antigens to T cells, thus blocking antigen presentation to autoreactive T cells thereby 
blocking B cell maturation. It has been tested in SLE patients with encouraging 
results [138].
2.5 Supplementary therapeutic modalities
Recently efforts have been made to incorporate adjunct therapeutic agents in the 
treatment of SLE, so, as to reduce the toxicity of traditional drugs. Prasterone and vita-
min D are two immunomodulatory agents, which have been applied in the treatment 
of SLE as supplements, in order to control disease activity and reduce the use of cor-
ticosteroids. Prasterone is a synthetic form of the hormone dehydroepiandrosterone 
[139]. Its use led SLE patients to better tolerate the tapering of corticosteroids [140] 
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and stabilized disease activity in some patients [141]. Vitamin D has immunomodula-
tory properties, namely it decreases inflammatory cytokines and down regulates the 
renin-angiotensin system [142, 143]. It may lead to the improvement of disease activity 
in SLE, as shown by some but not all studies [144–146].
3. Therapeutic strategies for the management of SLE
In 2014 a panel of experts introduced the treating-to-target approach in the 
management of SLE [147]. In 2019 an update of the EULAR recommendations for 
the management of SLE was published [148]. These recommendations are based 
both on evidence as well as on expert opinion. According to these recommendations, 
hydroxychloroquine should be administered to all lupus patients at a dose not exceed-
ing 5 mg/kg real body weight. During chronic maintenance therapy glucocorticoids 
should be minimized to less than 7.5 mg/day and withdrawn if possible. Initiation 
of immunomodulatory agents can aid in tapering or withdrawal of corticosteroids. 
In active or flaring extra-renal disease belimumab should be considered. Rituximab 
is an option for organ-threatening refractory disease. Various approaches for the 
treatment of SLE are currently under investigation. These include various methods 
to target interferon I, such as the use of anifrolumab, a human monoclonal antidoy 
to type I interferon receptor subunit 1[149, 150], and to inhibit T cell co-stimulation 
[151]. Baricitinib, an oral selective Janus kinase1 and Janus kinase 2 inhibitor is an oral 
treatment, which was tested in SLE patients with favorable results [152].
4. Conclusion
Hydroxychloroquine and prednisone remain standard of care treatment for SLE. 
When flares occur the introduction of immunosuppressive agents and/or biologic 
drugs improves disease activity and disease outcome in SLE. Nowadays, the intro-
duction of biologic agents, such as rituximab and belimumab have revolutionized 
the treatment of SLE and have opened new therapeutic horizons in all the spectrum 
of lupus disease.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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